RESPIRATORY TECHNOLOGIES, INC

Respiratory Technologies, Inc. specializes in the design, development, and manufacturing of advanced respiratory medical devices and associated diagnostic systems, operating within the medical device manufacturing sector under NAICS 334510. The company’s technical expertise centers on precision engineering of ventilators, oxygen delivery systems, and patient monitoring interfaces, with a focus on biocompatible materials, low-power embedded systems, and FDA-regulated software validation. Their work emphasizes clinical reliability, patient safety protocols, and compliance with ISO 13485 quality management standards, ensuring seamless integration into hospital and home care environments. Key differentiators include proprietary sensor fusion algorithms for respiratory pattern analysis and modular hardware architectures that enable rapid customization for pediatric, geriatric, and critical care applications. No award history is available to infer specific agency engagements or procurement patterns. Consequently, there is insufficient data to characterize relationships with federal, state, or defense healthcare entities. The company’s primary industry focus is medical device manufacturing, specifically within respiratory therapy equipment. This vertical involves developing Class II and Class III devices subject to rigorous FDA premarket notification and design control requirements. The firm positions itself as a niche provider of high-integrity respiratory solutions, serving clinical settings requiring continuous physiological monitoring and adaptive ventilation support. Respiratory Technologies, Inc. is structured as a small business under the 2L entity classification and is headquartered in Minneapolis, Minnesota. While the company holds no formal government certifications such as 8(a), HUBZone, or WOSB, its operational framework aligns with FDA Quality System Regulation and ISO standards critical for federal medical supply chains. Its geographic presence supports regional distribution networks and potential participation in federal medical procurement channels through direct manufacturer channels.